|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Integrated genomic analyses of ovarian
carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
|
|
3
|
Levanon K, Crum C and Drapkin R: New
insights into the pathogenesis of serous ovarian cancer and its
clinical impact. J Clin Oncol. 26:5284–5293. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li J, Fadare O, Xiang L, Kong B and Zheng
W: Ovarian serous carcinoma: recent concepts on its origin and
carcinogenesis. J Hematol Oncol. 5:82012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Z, Liu J, Segura MF, et al:
MiR-182 overexpression in tumourigenesis of high-grade
serous ovarian carcinoma. J Pathol. 228:204–215. 2012. View Article : Google Scholar
|
|
6
|
Kim J, Coffey DM, Creighton CJ, Yu Z,
Hawkins SM and Matzuk MM: High-grade serous ovarian cancer arises
from fallopian tube in a mouse model. Proc Natl Acad Sci USA.
109:3921–3926. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Z, Gersbach E, Zhang X, et al:
miR-106a represses the RB tumor suppressor p130 to regulate
cellular proliferation and differentiation in high-grade serous
ovarian carcinoma. Mol Cancer Res. 11:1314–1325. 2013. View Article : Google Scholar
|
|
8
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vergara D, Merlot B, Lucot JP, et al:
Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett.
291:59–66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Berx G, Raspé E, Christofori G, Thiery JP
and Sleeman JP: Pre-EMTing metastasis? Recapitulation of
morphogenetic processes in cancer. Clin Exp Metastasis. 24:587–597.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang G, Yuan J and Li K: EMT transcription
factors: implication in osteosarcoma. Med Oncol. 30:6972013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spaderna S, Schmalhofer O, Wahlbuhl M, et
al: The transcriptional repressor ZEB1 promotes metastasis and loss
of cell polarity in cancer. Cancer Res. 68:537–544. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Das E, Jana NR and Bhattacharyya NP:
MicroRNA-124 targets CCNA2 and regulates cell cycle in
STHdhQ111/HdhQ111
cells. Biochem Biophys Res Commun. 437:217–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakano H, Yamada Y, Miyazawa T and Yoshida
T: Gain-of-function microRNA screens identify miR-193a regulating
proliferation and apoptosis in epithelial ovarian cancer cells. Int
J Oncol. 42:1875–1882. 2013.PubMed/NCBI
|
|
16
|
Icli B, Wara AK, Moslehi J, et al:
MicroRNA-26a regulates pathological and physiological angiogenesis
by targeting BMP/SMAD1 signaling. Circ Res. 113:1231–1241. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calin GA, Dumitru CD, Shimizu M, et al:
Frequent deletions and down-regulation of micro- RNA genes
miR15 and miR16 at 13q14 in chronic lymphocytic
leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002.PubMed/NCBI
|
|
18
|
Dahiya N and Morin PJ: MicroRNAs in
ovarian carcinomas. Endocr Relat Cancer. 17:F77–F89. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bendoraite A, Knouf EC, Garg KS, et al:
Regulation of miR-200 family microRNAs and ZEB transcription
factors in ovarian cancer: evidence supporting a
mesothelial-to-epithelial transition. Gynecol Oncol. 116:117–125.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Wang L, Matyunina LV, Hill CG and
McDonald JF: Overexpression of miR-429 induces
mesenchymal-to-epithelial transition (MET) in metastatic ovarian
cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cao M, Seike M, Soeno C, et al: MiR-23a
regulates TGF-β-induced epithelial-mesenchymal transition by
targeting E-cadherin in lung cancer cells. Int J Oncol. 41:869–875.
2012.
|
|
22
|
Ru P, Steele R, Newhall P, Phillips NJ,
Toth K and Ray RB: miRNA-29b suppresses prostate cancer metastasis
by regulating epithelial-mesenchymal transition signaling. Mol
Cancer Ther. 11:1166–1173. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yokobori T, Suzuki S, Tanaka N, et al:
MiR-150 is associated with poor prognosis in esophageal
squamous cell carcinoma via targeting the EMT inducer ZEB1.
Cancer Sci. 104:48–54. 2013. View Article : Google Scholar
|
|
24
|
Buys SS, Partridge E, Black A, et al:
Effect of screening on ovarian cancer mortality: the Prostate,
Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized
Controlled Trial. JAMA. 305:2295–2303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sempere LF, Christensen M, Silahtaroglu A,
et al: Altered microRNA expression confined to specific epithelial
cell subpopulations in breast cancer. Cancer Res. 67:11612–11620.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schaefer A, Jung M, Mollenkopf HJ, et al:
Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
|
|
27
|
Sato K, Yoshimura A, Kaneko T, et al: A
single nucleotide polymorphism in 3′-untranslated region
contributes to the regulation of Toll-like receptor 4 translation.
J Biol Chem. 287:25163–25172. 2012.
|
|
28
|
Jones D, Li Y, He Y, Xu Z, Chen H and Min
W: Mirtron microRNA-1236 inhibits VEGFR-3 signaling during
inflammatory lymphangiogenesis. Arterioscler Thromb Vasc Biol.
32:633–642. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yokoyama Y, Charnock-Jones DS, Licence D,
et al: Vascular endothelial growth factor-D is an independent
prognostic factor in epithelial ovarian carcinoma. Br J Cancer.
88:237–244. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim KH, Jo MS, Suh DS, et al: Expression
and significance of the TLR4/MyD88 signaling pathway in ovarian
epithelial cancers. World J Surg Oncol. 10:1932012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu Y, Huang JM, Zhang GN, Zha X and Deng
BF: Prognostic significance of MyD88 expression by human epithelial
ovarian carcinoma cells. J Transl Med. 10:772012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klasa-Mazurkiewicz D, Jarząb M, Milczek T,
Lipińska B and Emerich J: Clinical significance of VEGFR-2 and
VEGFR-3 expression in ovarian cancer patients. Pol J Pathol.
62:31–40. 2011.PubMed/NCBI
|
